Biomarkers: Technologies and Global Markets

  • ID: 3757816
  • Report
  • Region: Global
  • 203 Pages
  • BCC Research
20 % OFF
until Jun 30th 2018
1 of 5
The Global Biomarkers Market is Expected to Grow at a five-year CAGR of 13.8% from 2015 to 2020

FEATURED COMPANIES

  • Abbott Laboratories Inc.
  • Bayer Schering Pharma Ag
  • Caprion Proteomics Inc.
  • Eisai Co. Ltd.
  • Genomic Health
  • Monogram Biosciences
  • MORE
The global biomarkers market has grown to $39.4 billion in 2014 from $29.3 billion in 2013. The market is expected to grow at a five-year compound annual growth rate (CAGR) of 13.8% from 2015 to 2020, increasing from $50.6 billion in 2015 to $96.6 billion in 2020.

This report provides:

- An overview of the global markets for biomarkers.

- Analyses of global market trends, with data from 2014, estimates for 2015, and projections of compound annual growth rates (CAGRs) through 2020.

- Assessments of companies poised to introduce products during the forecast period and discussion on how these introductions will change the face of the competitive environment.

- A range of information from detailed product analyses within disease subsegments to overall industry trends.

- A look at how market growth is expected in emerging geographies, driven by the growing middle class in emerging countries such as India, China, Brazil, and Russia.

- Profiles of manufacturers of leading products as well as biotechnology companies with novel products in development.

Current and projected product forecasts during the forecast period (2015 to 2020) are discussed. As well, new products approved in 2013 and 2014 by the FDA and those products expected to be approved within the forecast period are projected. Due to the release timing of this report, 2015 figures are estimated except where actual results have been reported.

The report includes analysis of leading and emerging competitors in the current worldwide biomarkers market. Profiles of manufacturers of leading products as well as biotechnology companies with novel products in development are analyzed to define specific product strategies that were employed.

This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products and technologies are influencing the current standard of care. Detailed profiles of current market leaders, as well as companies with innovative products poised to advance within the forecast period, are discussed.

Market figures are based on revenues at the manufacturers’ level and are projected at 2015 dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, new product introductions, expanded indications for existing products and projected changes in the prevalence, diagnosis and scripting rates for certain diseases.

Included in this report are forecasts by product, product category and by company from 2015 through 2020. The study is arranged to offer an overview of the biomarkers market accompanied by product, company, geography and mechanism of action, with forecasts broken down and covered by geographic region or country. Virtually the entire globe is covered in order to include prevalent data for each disease subsegment.

Excluded from this report are over-the-counter (OTC) medications and other consumables that do not require a physician’s prescription.

Sales figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.

All market share data presented is on a global basis unless specifically noted.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Laboratories Inc.
  • Bayer Schering Pharma Ag
  • Caprion Proteomics Inc.
  • Eisai Co. Ltd.
  • Genomic Health
  • Monogram Biosciences
  • MORE
1: Introduction
- Study Goals And Objectives
- Reasons For Doing The Study
- Scope Of Report
- Intended Audience
- Methodology And Information Sources
- Analyst's Credentials
- Disclaimer

2: Summary
- Biomarker Market Segments
- Table Summary : Global Biomarkers Market, By Segment, Through 2020
- Figure Summary : Global Biomarkers Market, By Segment, 2013-2020

- 3: Overview
- Introduction
- Types Of Biomarkers
- Cost Reduction Opportunities Arising From Biomarker Applications
- Strategic Biomarker Applications
- New Effort Aimed At Dose Selection
- Summary Of Recommendations For Effective Biomarker Evaluation
- Biomarkers: Challenges And Opportunities
- Product Summary And Market
- Cancer Biomarkers - Adoption Is Driving Growth
- Biomarker Market Forecast

4: Regulatory Dynamics, Intellectual Property And Ethical Considerations
- Introduction
- Biomarker Laboratory Regulatory Summary
- European Medicines Agency

5: Application By Therapy
- Overview
- Oncology
- Lung Cancer
- Clinical Biomarkers - Therapeutic Disease Market Forecast

6: Biomarkers Actively Guiding Drug Development
- Introduction
- Asuragen Inc.
- Bg Medicine
- Biomerieux
- Celera Corporation
- Curidium
- Dako North America Inc.
- Dxs
- Ge Healthcare
- Genomic Health
- Historx
- Laboratory Corporation Of America Holdings/Labcorp
- Mdxhealth
- Monogram Biosciences
- Xdx (Caredx)

7: Company Analysis
- Abbott Laboratories Inc.
- Affymetrix Inc.
- Astellas Pharma Inc.
- Astrazeneca Ltd.
- Banyan Biomarkers Inc.
- Bayer Schering Pharma Ag
- Bg Medicine Inc.
- Biophysical Corp.
- Biosystems International Inc.
- Boehringer Ingelheim Gmbh
- Bristol-Myers Squibb Co.
- Caprion Proteomics Inc.
- Daiichi Sankyo Co. Ltd.
- Eisai Co. Ltd.
- Eli Lilly And Co.
- Epigenomics Ag
- Genedata Ag
- Genenews Ltd.
- Glaxosmithkline
- Johnson & Johnson Ltd.
- Merck & Co.
- Novartis Ag
- Pfizer Inc.
- Roche Ltd.
- Sanofi-Aventis
- Takeda Pharmaceuticals Ltd.
- Teva Pharmaceutical Industries Ltd.

List Of Tables

Summary Table : Global Biomarkers Market, By Segment, Through 2020
Table 1 : Global Biomarkers Market, By Segment, Through 2020
Table 2 : Global Market For Biomarkers, By Segment, Through 2015
Table 3 : Global Biomarkers Market Growth In Drug Discovery, Through 2020
Table 4 : Companion Diagnostics Developed In-House Or With Collaborators
Table 5 : Percentage Of Cancer Patients Who Will Have A Predictive Biomarker, By Segment, 2010-2020
Table 6 : Frequency Of Approach In Claims Review, By Payers, 2013-2020
Table 7 : Relative Importance For Reimbursement Decisions Based On Test Factors, 2009-2015
Table 8 : U.S. Healthcare Spending, 2013
Table 9 : Year-Over-Year Precent Growth In Spending, By Category, 2011-2012 And 2012-2013
Table 10 : Personalized Treatment Options For Breast Cancer
Table 11 : Cns Biomarkers By Disease/Condition
Table 12 : Information Technology (It) Strategies
Table 13 : Initial Designs And Capabilities For Clinical Trials
Table 14 : Benefits Of Biomarkers As Surrogate Endpoints
Table 15 : Novel Dose Selection Biomarkers Used In Cancer, Diabetes, Metabolic And Liver Disease
Table 16 : Patient Outcome Measurements Biomarkers
Table 17 : Biomarker And Clinical Endpoint One
Table 18 : Biomarker And Clinical Endpoint Two
Table 19 : Biomarker Indication Of Severity To Improve Outcome
Table 20 : Clinical Trial Pipeline-Phase Of Intervention Development
Table 21 : Cross-Sectional Investigations
Table 22 : Global Biomarkers Market, By Segment, Through 2015
Table 23 : Clinicial Patient Monitoring By Subdisease
Table 24 : Global Biomarker Market, By Segment, Through 2020
Table 25 : Pharmacogenomic Biomarkers In Drug Labeling
Table 26 : Biomarker Categories And Types
Table 27 : Biomarker Qualification Program
Table 28 : Annual Patents Filed And Approved With Biomarker Claims In U.S., Europe, Japan, Through 2015
Table 29 : Global Market For Total Clinical Stage Biomarkers, By Segment, Through 2020
Table 30 : Summary Of Recent Agreements In Biomarker Delivery
Table 31 : Representative List Of Approved Biomarker Patents In The U.S., Europe And Japan
Table 32 : Global Market For Clinical Stage Biomarkers, By Therapeutic Area, Through 2020
Table 33 : Representative Biomarkers In Clinical Use - Oncology
Table 34 : Ongoing Representative Active Biomarker Trials For Breast Cancer, 2005-2009
Table 35 : Ongoing Representative Active Biomarker Trials In Oncology, 2005-2009
Table 36 : Ongoing Representative Active Biomarker Trials - Lung Cancer, 2006-2014
Table 37 : Representative Biomarkers In Clinical Use - Cns Disease, 2008-2013
Table 38 : Representative Biomarkers In Clinical Use - Immunology, 2013
Table 39 : Global Market For Clinical Stage Biomarkers, By Segment, Through 2020
Table 40 : Global Market Of Biomarkers In Late-Stage Clinical Use By Therapeutic Area, Through 2020
Table 41 : Recent Corporate Alliances Between Biomarkers And Drug Development Companies
Table 42 : Abbott: Representative Clinical Trials Involving Biomarkers
Table 43 : Affymetrix: Representative Clinical Trials Involving Biomarkers
Table 44 : Astellas: Representative Clinical Trials Involving Biomarkers
Table 45 : Astrazeneca: Representative Clinical Trials Involving Biomarkers
Table 46 : Banyan Biomarkers Representative Clinical Trials Involving Biomarkers
Table 47 : Bayer Schering: Representative Clinical Trials Involving Biomarkers
Table 48 : Biophysical: Representative Clinical Trials Involving Biomarkers
Table 49 : Biosystems: Representative Clinical Trials Involving Biomarkers
Table 50 : Bms: Representative Clinical Trials Involving Biomarkers
Table 51 : Daiichi Sankyo: Representative Clinical Trials Involving Biomarkers
Table 52 : Eisai: Representative Clinical Trials Involving Biomarkers
Table 53 : Eli Lilly: Representative Clinical Trials Involving Biomarkers
Table 54 : Epigenomics: Representative Clinical Trials Involving Biomarkers
Table 55 : Genedata Ag: Representative Clinical Trials Involving Biomarkers
Table 56 : Gsk: Representative Clinical Trials Involving Biomarkers
Table 57 : Johnson & Johnson: Representative Clinical Trials Involving Biomarkers
Table 58 : Merck: Representative Clinical Trials Involving Biomarkers
Table 59 : Novartis: Representative Clinical Trials Involving Biomarkers
Table 60 : Pfizer: Representative Clinical Trials Involving Biomarkers
Table 61 : Roche: Representative Clinical Trials Involving Biomarkers
Table 62 : Sanofi-Aventis: Representative Clinical Trials Involving Biomarkers
Table 63 : Takeda Pharmaceuticals: Representative Clinical Trials Involving Biomarkers
Table 64 : Teva Pharmaceutical: Representative Clinical Trials Involving Biomarkers

List Of Figures

Summary Figure : Global Biomarkers Market, By Segment, 2013-2020
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
- Abbott Laboratories Inc.
- Affymetrix Inc.
- Astellas Pharma Inc.
- Astrazeneca Ltd.
- Asuragen Inc.
- Banyan Biomarkers Inc.
- Bayer Schering Pharma Ag
- Bg Medicine Inc.
- Biomerieux
- Biophysical Corp.
- Biosystems International Inc.
- Boehringer Ingelheim Gmbh
- Bristol-Myers Squibb Co.
- Caprion Proteomics Inc.
- Celera Corporation
- Curidium
- Daiichi Sankyo Co. Ltd.
- Dako North America Inc.
- Dxs
- Eisai Co. Ltd.
- Eli Lilly And Co.
- Epigenomics Ag
- Ge Healthcare
- Genedata Ag
- Genenews Ltd.
- Genomic Health
- Glaxosmithkline
- Historx
- Johnson & Johnson Ltd.
- Laboratory Corporation Of America Holdings/Labcorp
- Mdxhealth
- Merck & Co.
- Monogram Biosciences
- Novartis Ag
- Pfizer Inc.
- Roche Ltd.
- Sanofi-Aventis
- Takeda Pharmaceuticals Ltd.
- Teva Pharmaceutical Industries Ltd.
- Xdx (Caredx)
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll